These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

898 related items for PubMed ID: 14625161

  • 1. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L.
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [Abstract] [Full Text] [Related]

  • 2. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG.
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT, Ribeiro AB.
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 7. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar 09; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 8. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Kidney Int; 2004 Jun 09; 65(6):2309-20. PubMed ID: 15149345
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.
    Semin Nephrol; 2004 Mar 09; 24(2):147-57. PubMed ID: 15017527
    [Abstract] [Full Text] [Related]

  • 10. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
    Pisoni R, Faraone R, Ruggenent P, Remuzzi G.
    J Nephrol; 2002 Mar 09; 15(4):428-30. PubMed ID: 12243375
    [Abstract] [Full Text] [Related]

  • 11. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.
    Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ.
    Lancet; 2005 Dec 10; 366(9502):2026-33. PubMed ID: 16338452
    [Abstract] [Full Text] [Related]

  • 12. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Dec 10; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.
    van der Sande NG, Dorresteijn JA, Visseren FL, Dwyer JP, Blankestijn PJ, van der Graaf Y, Heerspink HL.
    Diabetes Obes Metab; 2016 Nov 10; 18(11):1120-1127. PubMed ID: 27337598
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
    Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
    [Abstract] [Full Text] [Related]

  • 18. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
    Sica DA, Bakris GL.
    J Clin Hypertens (Greenwich); 2002 Jul 14; 4(1):52-7. PubMed ID: 11821641
    [Abstract] [Full Text] [Related]

  • 19. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D.
    Am J Kidney Dis; 2014 Feb 14; 63(2):244-50. PubMed ID: 24210590
    [Abstract] [Full Text] [Related]

  • 20. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
    Ball SG, White WB.
    Am J Cardiol; 2003 May 22; 91(10A):15G-21G. PubMed ID: 12781904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.